Infant Bacterial Therapeutics vs 80 Acres Farms

Side-by-side comparison of AI visibility scores, market position, and capabilities

Infant Bacterial Therapeutics

EmergingBioTech

Pediatric Medicine

Infant Bacterial Therapeutics (IBT) is developing live biotherapeutic Lactobacillus reuteri DSM17938 for necrotizing enterocolitis prevention in premature infants, with Phase 3 trial results expected in 2026.

About

Infant Bacterial Therapeutics (IBT) is a Swedish biopharma company developing Lactobacillus reuteri DSM17938 — a probiotic bacterial strain — as a regulated drug (live biotherapeutic product) to prevent necrotizing enterocolitis (NEC) in premature infants. NEC is a devastating gastrointestinal emergency affecting 1–7% of premature newborns, with 30% mortality and severe long-term outcomes in survivors. No approved preventive treatments exist, despite decades of evidence suggesting certain probiotic strains reduce NEC incidence.

Full profile

80 Acres Farms

ChallengerAgTech

Indoor Vertical Farming

Raised $115M (Feb 2026) led by General Atlantic. Post-merger with Soli Organic creates largest indoor farm in North America. ~$200M combined first-year revenues.

About

80 Acres Farms is a commercial-scale indoor vertical farming company that, following its merger with Soli Organic, operates the largest indoor farming network in North America. The company raised $115 million in February 2026 led by General Atlantic, with projected first-year combined revenues approaching $200 million — making it one of the few vertical farming companies to achieve genuine commercial scale after years of industry attrition that eliminated several high-profile competitors.

Full profile

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.